BACKGROUND: The aim of this study was to evaluate the efficacy of using matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9)-cleavable ratiometric activatable cell-penetrating peptides (RACPPs) conjugated to Cy5 and Cy7 fluorophores to accurately label pancreatic cancer for fluorescence-guided surgery (FGS) in an orthotopic mouse model. METHODS: Orthotopic mouse models were established using MiaPaCa-2-GFP human pancreatic cancer cells. Two weeks after implantation, tumor-bearing mice were randomized to conventional white light reflectance (WLR) surgery or FGS. FGS was performed at far-red and infrared wavelengths with a customized fluorescence-dissecting microscope 2 h after injection of MMP-2 and MMP-9-cleavable RACPPs. Green fluorescence imaging of the GFP-labeled cancer cells was used to assess the effectiveness of surgical resection and monitor recurrence. At 8 weeks, mice were sacrificed to evaluate tumor burden and metastases. RESULTS: Mice in the WLR group had larger primary tumors than mice in the FGS group at termination [1.72 g ± standard error (SE) 0.58 vs. 0.25 g ± SE 0.14; respectively, p = 0.026). Mean disease-free survival was significantly lengthened from 5.33 weeks in the WLR group to 7.38 weeks in the FGS group (p = 0.02). Recurrence rates were lower in the FGS group than in the WLR group (38 vs. 73 %; p = 0.049). This translated into lower local and distant recurrence rates for FGS compared to WLR (31 vs. 67 for local recurrence, respectively, and 25 vs. 60 % for distant recurrence, respectively). Metastatic tumor burden was significantly greater in the WLR group than in the FGS group (96.92 mm(2) ± SE 52.03 vs. 2.20 mm(2) ± SE 1.43; respectively, χ (2) = 5.455; p = 0.02). CONCLUSIONS: RACPPs can accurately and effectively label pancreatic cancer for effective FGS, resulting in better postresection outcomes than for WLR surgery.
BACKGROUND: The aim of this study was to evaluate the efficacy of using matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9)-cleavable ratiometric activatable cell-penetrating peptides (RACPPs) conjugated to Cy5 and Cy7 fluorophores to accurately label pancreatic cancer for fluorescence-guided surgery (FGS) in an orthotopic mouse model. METHODS: Orthotopic mouse models were established using MiaPaCa-2-GFP humanpancreatic cancer cells. Two weeks after implantation, tumor-bearing mice were randomized to conventional white light reflectance (WLR) surgery or FGS. FGS was performed at far-red and infrared wavelengths with a customized fluorescence-dissecting microscope 2 h after injection of MMP-2 and MMP-9-cleavable RACPPs. Green fluorescence imaging of the GFP-labeled cancer cells was used to assess the effectiveness of surgical resection and monitor recurrence. At 8 weeks, mice were sacrificed to evaluate tumor burden and metastases. RESULTS:Mice in the WLR group had larger primary tumors than mice in the FGS group at termination [1.72 g ± standard error (SE) 0.58 vs. 0.25 g ± SE 0.14; respectively, p = 0.026). Mean disease-free survival was significantly lengthened from 5.33 weeks in the WLR group to 7.38 weeks in the FGS group (p = 0.02). Recurrence rates were lower in the FGS group than in the WLR group (38 vs. 73 %; p = 0.049). This translated into lower local and distant recurrence rates for FGS compared to WLR (31 vs. 67 for local recurrence, respectively, and 25 vs. 60 % for distant recurrence, respectively). Metastatic tumor burden was significantly greater in the WLR group than in the FGS group (96.92 mm(2) ± SE 52.03 vs. 2.20 mm(2) ± SE 1.43; respectively, χ (2) = 5.455; p = 0.02). CONCLUSIONS:RACPPs can accurately and effectively label pancreatic cancer for effective FGS, resulting in better postresection outcomes than for WLR surgery.
Authors: Michael Bouvet; Jinwei Wang; Stephanie R Nardin; Rounak Nassirpour; Meng Yang; Eugene Baranov; Ping Jiang; A R Moossa; Robert M Hoffman Journal: Cancer Res Date: 2002-03-01 Impact factor: 12.701
Authors: Tao Jiang; Emilia S Olson; Quyen T Nguyen; Melinda Roy; Patricia A Jennings; Roger Y Tsien Journal: Proc Natl Acad Sci U S A Date: 2004-12-15 Impact factor: 11.205
Authors: Brendon M Stiles; Amit Bhargava; Prasad S Adusumilli; Stephen F Stanziale; Teresa H Kim; Valerie W Rusch; Yuman Fong Journal: Surgery Date: 2003-08 Impact factor: 3.982
Authors: Matthew H Katz; Shinako Takimoto; Daniel Spivack; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: J Surg Res Date: 2003-07 Impact factor: 2.192
Authors: Andrea Picchetto; Barbara Seeliger; Stefania La Rocca; Manuel Barberio; Giancarlo D'Ambrosio; Jacques Marescaux; Michele Diana Journal: Chirurg Date: 2019-11 Impact factor: 0.955
Authors: Cassandra E Callmann; Christopher V Barback; Matthew P Thompson; David J Hall; Robert F Mattrey; Nathan C Gianneschi Journal: Adv Mater Date: 2015-07-14 Impact factor: 30.849
Authors: Ray R Zhang; Alexandra B Schroeder; Joseph J Grudzinski; Eben L Rosenthal; Jason M Warram; Anatoly N Pinchuk; Kevin W Eliceiri; John S Kuo; Jamey P Weichert Journal: Nat Rev Clin Oncol Date: 2017-01-17 Impact factor: 66.675
Authors: Bowen Qi; Ayrianne J Crawford; Nicholas E Wojtynek; Megan B Holmes; Joshua J Souchek; Graca Almeida-Porada; Quan P Ly; Samuel M Cohen; Michael A Hollingsworth; Aaron M Mohs Journal: Nanomedicine Date: 2018-01-09 Impact factor: 5.307
Authors: Yukihiko Hiroshima; Thinzar M Lwin; Takashi Murakami; Ali A Mawy; Tanaka Kuniya; Takashi Chishima; Itaru Endo; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454
Authors: Ryan K Orosco; Elamprakash N Savariar; Philip A Weissbrod; Julio A Diaz-Perez; Michael Bouvet; Roger Y Tsien; Quyen T Nguyen Journal: J Surg Oncol Date: 2016-01-12 Impact factor: 3.454